Cost evaluation of rhythm control methods for atrial fibrillation: Evidence from CTAF

Cardiac Electrophysiology Review

Volumn 7, Issue 3, 2003, Pages 211-214

  Nattel, Stanley ^a   Lumer, Gerald ^a   Talajic, Mario ^a   Roy, Denis ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Anti arrhythmia agents; Atrial fibrillation; Clinical trial; Cost benefit analysis; Randomized clinical trial

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; PROPAFENONE; SOTALOL; WARFARIN;

BODY WEIGHT DISORDER; CANADA; CARDIOVERSION; CLINICAL TRIAL; CONTROL STRATEGY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; LUNG FIBROSIS; LUNG TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SINUS RHYTHM; SYMPTOMATOLOGY;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; PROPAFENONE; SOTALOL;

EID: 1342302433     PISSN: 13852264     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CEPR.0000012384.57261.71     Document Type: Review

References (17)

1. Nattel S, Khairy P, Roy D, Thibault B, Guerra P, Talajic M, Dubuc M. New approaches to atrial fibrillation management - A critical review of a rapidly-evolving field. Drugs 2002;62:2377-2397.
2. Lumer GB, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, Thibault B, Dubuc M, Gagné P, Nattel S. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Eur Heart J 2002;23:1050-1056.
3. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagné P, Nattel S, Thibault B. Amiodarone to Prevent Recurrences of Atrial Fibrillaiton, The Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920.
4. Vorperian KR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997;30:791-798.
5. Singh SN, Fisher SG, Deedwania PC, Rohatgi P, Singh BN, Fletcher RD. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT). J Am Coll Cardiol 1997;30:514-517.
6. Mahoney EM, Thompson TD, Veledar E, Williams J, Weintraub WS. Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation. J Am Coll Cardiol 2002;40:737-745.
7. Lanza LA, Visbal AI, DeValeria PA, Zinsmeister AR, Diehl NN, Trastek VF. Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection. Ann Thorac Surg 2003;75:223-230.
8. Reddy P, Dunn AB, White CM, Tsikouris JP, Giri S, Kluger J. An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery. Pharmacotherapy 2002;22:75-80.
9. Reddy P, Song J. Cost comparisons of pharmacological strategies in open-heart surgery. Pharmacoeconomics 2003;21:249-262.
10. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med 1998;158:1669-1677.
11. Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, Birkmeyer JD. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med 1999;130:625-636.
12. Nattel S, Talajic M, Fermini B, Roy D. Amiodarone - Pharmacology, clinical actions, and relationships between them. J Cardiovasc Electrophysiol 1992;3:266-280.
13. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
14. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840.
15. Falk RH. Management of atrial fibrillation - Radical reform or modest modification? N Engl J Med 2002;347: 1883-1884.
16. Cain ME. Atrial fibrillation - Rhythm or rate control. N Engl J Med 2002;347:1822-1823.
17. Nattel S. Rhythm versus rate control for atrial fibrillation management - what recent randomized clinical trials allow us to affirm. Can Med Assoc J 2003;168:572-573.